IMP-1088

IMP-1088
Names
	Preferred IUPAC name 1-(5-{3,4-Difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl}-1-methyl-1H-indazol-3-yl)-N,N-dimethylmethanamine
Identifiers
CAS Number	2059148-82-0;
3D model (JSmol)	Interactive image;
PubChem CID	132274735;
	InChI Key: SOXNKJCQBRQUMS-UHFFFAOYSA-N;
	SMILES CC1=NN(C)C(=C1CCOC2=C(C=CC(=C2F)F)C3=CC=C4C(=C3)C(=NN4C)CN(C)C)C;
Properties
Chemical formula	C25H29F2N5O
Molar mass	453.538 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

IMP-1088 is an enzyme inhibitor of the human N-myristoyltransferases NMT1 and NMT2 capable of preventing rhinoviral replication,[1] an area of research relating to potential treatment of the common cold. IMP-1088 works to keep cells from generating infectious virus by targeting the cell instead of the rhinovirus itself. It does this by blocking the NMT protein of the host cell which prevents the virus from assembling its capsid, since viral capsid myristoylation by host NMT is essential for assembly. It is thought unlikely that viruses will evolve resistance to such an approach since IMP-1088 works against the human cell and not the virus.[2][3]

References

Mousnier, Aurélie; Bell, Andrew S.; Swieboda, Dawid P.; Morales-Sanfrutos, Julia; Pérez-Dorado, Inmaculada; Brannigan, James A.; Newman, Joseph; Ritzefeld, Markus; Hutton, Jennie A.; Guedán, Anabel; Asfor, Amin S.; Robinson, Sean W.; Hopkins-Navratilova, Iva; Wilkinson, Anthony J.; Johnston, Sebastian L.; Leatherbarrow, Robin J.; Tuthill, Tobias J.; Solari, Roberto; Tate, Edward W. (14 May 2018). "Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus". Nature Chemistry. 10 (6): 599–606. Bibcode:2018NatCh..10..599M. doi:10.1038/s41557-018-0039-2. PMC 6015761. PMID 29760414.
Borman, Stu. "Agent stops common cold virus replication". Chemical & Engineering News. Retrieved 20 May 2018.
Houser, Kristin (19 May 2018). "A team of researchers may have actually found a cure to the common cold". Business Insider. Retrieved 20 May 2018.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Mousnier, Aurélie; Bell, Andrew S.; Swieboda, Dawid P.; Morales-Sanfrutos, Julia; Pérez-Dorado, Inmaculada; Brannigan, James A.; Newman, Joseph; Ritzefeld, Markus; Hutton, Jennie A.; Guedán, Anabel; Asfor, Amin S.; Robinson, Sean W.; Hopkins-Navratilova, Iva; Wilkinson, Anthony J.; Johnston, Sebastian L.; Leatherbarrow, Robin J.; Tuthill, Tobias J.; Solari, Roberto; Tate, Edward W. (14 May 2018). "Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus". Nature Chemistry. 10 (6): 599–606. Bibcode:2018NatCh..10..599M. doi:10.1038/s41557-018-0039-2. PMC 6015761. PMID 29760414.

[2] Borman, Stu. "Agent stops common cold virus replication". Chemical & Engineering News. Retrieved 20 May 2018.

[3] Houser, Kristin (19 May 2018). "A team of researchers may have actually found a cure to the common cold". Business Insider. Retrieved 20 May 2018.